

Pierre Blanchard

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9472252/publications.pdf>

Version: 2024-02-01

244
papers

9,249
citations

76326

40
h-index

46799

89
g-index

293
all docs

293
docs citations

293
times ranked

9597
citing authors

#	ARTICLE	IF	CITATIONS
1	Nasopharyngeal carcinoma. <i>Lancet, The</i> , 2019, 394, 64-80.	13.7	1,667
2	Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis. <i>Lancet Oncology, The</i> , 2015, 16, 645-655.	10.7	593
3	Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): A comprehensive analysis by tumour site. <i>Radiotherapy and Oncology</i> , 2011, 100, 33-40.	0.6	534
4	Concomitant chemoradiotherapy versus acceleration of radiotherapy with or without concomitant chemotherapy in locally advanced head and neck carcinoma (GORTEC 99-02): an open-label phase 3 randomised trial. <i>Lancet Oncology, The</i> , 2012, 13, 145-153.	10.7	315
5	What Is the Best Treatment of Locally Advanced Nasopharyngeal Carcinoma? An Individual Patient Data Network Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2017, 35, 498-505.	1.6	263
6	Taxane-Cisplatin-Fluorouracil As Induction Chemotherapy in Locally Advanced Head and Neck Cancers: An Individual Patient Data Meta-Analysis of the Meta-Analysis of Chemotherapy in Head and Neck Cancer Group. <i>Journal of Clinical Oncology</i> , 2013, 31, 2854-2860.	1.6	253
7	Role of radiotherapy fractionation in head and neck cancers (MARCH): an updated meta-analysis. <i>Lancet Oncology, The</i> , 2017, 18, 1221-1237.	10.7	226
8	Clinical evidence of variable proton biological effectiveness in pediatric patients treated for ependymoma. <i>Radiotherapy and Oncology</i> , 2016, 121, 395-401.	0.6	210
9	Treatment de-escalation in HPV-positive oropharyngeal carcinoma: Ongoing trials, critical issues and perspectives. <i>International Journal of Cancer</i> , 2015, 136, 1494-1503.	5.1	199
10	Prevalence and causes of burnout amongst oncology residents: A comprehensive nationwide cross-sectional study. <i>European Journal of Cancer</i> , 2010, 46, 2708-2715.	2.8	181
11	Intensity-modulated proton beam therapy (IMPT) versus intensity-modulated photon therapy (IMRT) for patients with oropharynx cancer – A case matched analysis. <i>Radiotherapy and Oncology</i> , 2016, 120, 48-55.	0.6	177
12	Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group. <i>Radiotherapy and Oncology</i> , 2021, 156, 281-293.	0.6	157
13	Practice Recommendations for Risk-Adapted Head and Neck Cancer Radiation Therapy During the COVID-19 Pandemic: An ASTRO-ESTRO Consensus Statement. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 107, 618-627.	0.8	156
14	Brachytherapy: An overview for clinicians. <i>Ca-A Cancer Journal for Clinicians</i> , 2019, 69, 386-401.	329.8	150
15	Treatment de-escalation for HPV-driven oropharyngeal cancer: Where do we stand?. <i>Clinical and Translational Radiation Oncology</i> , 2018, 8, 4-11.	1.7	141
16	A randomized trial of induction docetaxel+cisplatin+5FU followed by concomitant cisplatin-RT versus concomitant cisplatin-RT in nasopharyngeal carcinoma (GORTEC 2006-02). <i>Annals of Oncology</i> , 2018, 29, 731-736.	1.2	140
17	Nodular regenerative hyperplasia is a new cause of chronic liver disease in HIV-infected patients. <i>Aids</i> , 2007, 21, 187-192.	2.2	123
18	Intensity Modulated Proton Therapy Versus Intensity Modulated Photon Radiation Therapy for Oropharyngeal Cancer: First Comparative Results of Patient-Reported Outcomes. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 95, 1107-1114.	0.8	121

#	ARTICLE	IF	CITATIONS
19	Prognostic impact of HPV-associated p16-expression and smoking status on outcomes following radiotherapy for oropharyngeal cancer: The MARCH-HPV project. <i>Radiotherapy and Oncology</i> , 2018, 126, 107-115.	0.6	116
20	Dosimetric Benefits of Intensity-Modulated Radiotherapy Combined With the Deep-Inspiration Breath-Hold Technique in Patients With Mediastinal Hodgkin's Lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 82, 1522-1527.	0.8	106
21	Intensity modulated proton therapy (IMPT) – The future of IMRT for head and neck cancer. <i>Oral Oncology</i> , 2019, 88, 66-74.	1.5	103
22	Predictive and prognostic value of CT based radiomics signature in locally advanced head and neck cancers patients treated with concurrent chemoradiotherapy or bioradiotherapy and its added value to Human Papillomavirus status. <i>Oral Oncology</i> , 2017, 71, 150-155.	1.5	92
23	Proton Therapy for Head and Neck Cancers. <i>Seminars in Radiation Oncology</i> , 2018, 28, 53-63.	2.2	89
24	Clinical Outcomes and Patterns of Disease Recurrence After Intensity Modulated Proton Therapy for Oropharyngeal Squamous Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 95, 360-367.	0.8	88
25	Toward a model-based patient selection strategy for proton therapy: External validation of photon-derived normal tissue complication probability models in a head and neck proton therapy cohort. <i>Radiotherapy and Oncology</i> , 2016, 121, 381-386.	0.6	78
26	Intensity-modulated proton therapy and osteoradionecrosis in oropharyngeal cancer. <i>Radiotherapy and Oncology</i> , 2017, 123, 401-405.	0.6	73
27	Dose-volume correlates of mandibular osteoradionecrosis in Oropharynx cancer patients receiving intensity-modulated radiotherapy: Results from a case-matched comparison. <i>Radiotherapy and Oncology</i> , 2017, 124, 232-239.	0.6	69
28	Dosimetric advantages of intensity-modulated proton therapy for oropharyngeal cancer compared with intensity-modulated radiation: A case-matched control analysis. <i>Medical Dosimetry</i> , 2016, 41, 189-194.	0.9	62
29	Mixed treatment comparison meta-analysis of altered fractionated radiotherapy and chemotherapy in head and neck cancer. <i>Journal of Clinical Epidemiology</i> , 2011, 64, 985-992.	5.0	56
30	Isolated lymph node relapse of epithelial ovarian carcinoma: Outcomes and prognostic factors. <i>Gynecologic Oncology</i> , 2007, 104, 41-45.	1.4	55
31	Radiation therapy dose is associated with improved survival for unresected anaplastic thyroid carcinoma: Outcomes from the National Cancer Data Base. <i>Cancer</i> , 2017, 123, 1653-1661.	4.1	55
32	Hyperfractionated or accelerated radiotherapy for head and neck cancer. <i>The Cochrane Library</i> , 2015, .	2.8	52
33	Neutrophils, a candidate biomarker and target for radiation therapy?. <i>Acta Oncologica</i> , 2017, 56, 1522-1530.	1.8	50
34	Effect of Amifostine on Survival Among Patients Treated With Radiotherapy: A Meta-Analysis of Individual Patient Data. <i>Journal of Clinical Oncology</i> , 2011, 29, 2590-2597.	1.6	49
35	Radiation-Related Alterations of Taste Function in Patients With Head and Neck Cancer: a Systematic Review. <i>Current Treatment Options in Oncology</i> , 2018, 19, 72.	3.0	49
36	A biochemical definition of cure after brachytherapy for prostate cancer. <i>Radiotherapy and Oncology</i> , 2020, 149, 64-69.	0.6	48

#	ARTICLE	IF	CITATIONS
37	Anaplastic Thyroid Carcinoma: An Update. <i>Cancers</i> , 2022, 14, 1061.	3.7	47
38	Chemotherapy and radiotherapy in locally advanced head and neck cancer: an individual patient data network meta-analysis. <i>Lancet Oncology</i> , The, 2021, 22, 727-736.	10.7	45
39	Concurrent use of cisplatin or cetuximab with definitive radiotherapy for locally advanced head and neck squamous cell carcinomas. <i>Strahlentherapie Und Onkologie</i> , 2014, 190, 823-831.	2.0	44
40	Smoking impact on HPV driven head and neck cancer's oncological outcomes?. <i>Oral Oncology</i> , 2018, 82, 131-137.	1.5	44
41	Induction chemotherapy with docetaxel, cisplatin and fluorouracil followed by concurrent chemoradiotherapy or chemoradiotherapy alone in locally advanced non-endemic nasopharyngeal carcinoma. <i>Oral Oncology</i> , 2016, 62, 114-121.	1.5	43
42	Outcomes and prognostic factors for squamous cell carcinoma of the oral tongue in young adults: a single-institution case-matched analysis. <i>European Archives of Oto-Rhino-Laryngology</i> , 2017, 274, 1683-1690.	1.6	43
43	Outcomes of multimodal management for sinonasal squamous cell carcinoma. <i>Journal of Cranio-Maxillo-Facial Surgery</i> , 2017, 45, 1124-1132.	1.7	42
44	Prospective Phase 2 Trial of Permanent Seed Implantation Prostate Brachytherapy for Intermediate-Risk Localized Prostate Cancer: Efficacy, Toxicity, and Quality of Life Outcomes. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 374-382.	0.8	42
45	Multimodal treatment and long-term outcome of patients with esthesioneuroblastoma. <i>Oral Oncology</i> , 2013, 49, 830-834.	1.5	41
46	Magnetic Resonance-based Response Assessment and Dose Adaptation in Human Papilloma Virus Positive Tumors of the Oropharynx treated with Radiotherapy (MR-ADAPTOR): An R-IDEAL stage 2a-2b/Bayesian phase II trial. <i>Clinical and Translational Radiation Oncology</i> , 2018, 13, 19-23.	1.7	41
47	Chemotherapy for Nasopharyngeal Carcinoma " Current Recommendation and Controversies. <i>Hematology/Oncology Clinics of North America</i> , 2015, 29, 1107-1122.	2.2	39
48	Assessing head and neck cancer patient preferences and expectations: A systematic review. <i>Oral Oncology</i> , 2016, 62, 44-53.	1.5	39
49	Brachytherapy for Conservative Treatment of Invasive Penile Carcinoma: Prognostic Factors and Long-Term Analysis of Outcome. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, 563-570.	0.8	39
50	Surrogate End Points for Overall Survival in Loco-Regionally Advanced Nasopharyngeal Carcinoma: An Individual Patient Data Meta-analysis. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	6.3	37
51	Delineation in thoracic oncology: a prospective study of the effect of training on contour variability and dosimetric consequences. <i>Radiation Oncology</i> , 2011, 6, 118.	2.7	36
52	Clinical relevance of tumor infiltrating lymphocytes, PD-L1 expression and correlation with HPV/p16 in head and neck cancer treated with bio- or chemo-radiotherapy. <i>Oncolmmunology</i> , 2017, 6, e1341030.	4.6	36
53	Endorectal advancement flap with muscular plication: a modified technique for rectovaginal fistula repair. <i>Colorectal Disease</i> , 2011, 13, 921-925.	1.4	32
54	Personalizing treatment in patients with castrate-resistant prostate cancer: A study of predictive factors for secondary endocrine therapies activity.. <i>Journal of Clinical Oncology</i> , 2012, 30, 213-213.	1.6	32

#	ARTICLE	IF	CITATIONS
55	Locoregional symptoms in patients with de novo metastatic prostate cancer: Morbidity, management, and disease outcome. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 202.e9-202.e17.	1.6	31
56	Predicting and preventing thromboembolic events in patients receiving cisplatin-based chemotherapy for germ cell tumours. <i>European Journal of Cancer</i> , 2016, 69, 151-157.	2.8	31
57	Clinical use of magnetic resonance imaging across the prostate brachytherapy workflow. <i>Brachytherapy</i> , 2017, 16, 734-742.	0.5	29
58	Outcome According to Elective Pelvic Radiation Therapy in Patients With High-Risk Localized Prostate Cancer: A Secondary Analysis of the GETUG 12 Phase 3 Randomized Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 94, 85-92.	0.8	28
59	Is there an increased risk of cancer among spouses of patients with an HPV-related cancer: A systematic review. <i>Oral Oncology</i> , 2017, 67, 138-145.	1.5	28
60	Prospective in silico study of the feasibility and dosimetric advantages of MRI-guided dose adaptation for human papillomavirus positive oropharyngeal cancer patients compared with standard IMRT. <i>Clinical and Translational Radiation Oncology</i> , 2018, 11, 11-18.	1.7	27
61	Prevalence of burnout, depression and job satisfaction among French senior and resident radiation oncologists. <i>Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique</i> , 2018, 22, 784-789.	1.4	26
62	Comparing Intensity-Modulated Proton Therapy With Intensity-Modulated Photon Therapy for Oropharyngeal Cancer: The Journey From Clinical Trial Concept to Activation. <i>Seminars in Radiation Oncology</i> , 2018, 28, 108-113.	2.2	26
63	Intensity-Modulated Proton Therapy Adaptive Planning for Patients with Oropharyngeal Cancer. <i>International Journal of Particle Therapy</i> , 2017, 4, 26-34.	1.8	26
64	Mobile Technology and Social Media in the Clinical Practice of Young Radiation Oncologists: Results of a Comprehensive Nationwide Cross-sectional Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 90, 231-237.	0.8	25
65	Human papillomavirus status and the relative biological effectiveness of proton radiotherapy in head and neck cancer cells. <i>Head and Neck</i> , 2017, 39, 708-715.	2.0	24
66	Inter-observer variability in target delineation increases during adaptive treatment of head-and-neck and lung cancer. <i>Acta Oncologica</i> , 2019, 58, 1378-1385.	1.8	24
67	Practice recommendations for risk-adapted head and neck cancer radiotherapy during the COVID-19 pandemic: An ASTRO-ESTRO consensus statement. <i>Radiotherapy and Oncology</i> , 2020, 151, 314-321.	0.6	24
68	Accelerated radiotherapy and concomitant high dose chemotherapy in non resectable stage IV locally advanced HNSCC: Results of a GORTEC randomized trial. <i>Radiotherapy and Oncology</i> , 2011, 100, 56-61.	0.6	23
69	Concurrent chemoradiotherapy with cisplatin or cetuximab for locally advanced head and neck squamous cell carcinomas: Does human papilloma virus play a role?. <i>Oral Oncology</i> , 2016, 59, 50-57.	1.5	23
70	Influence of tumor-associated macrophages and HLA class I expression according to HPV status in head and neck cancer patients receiving chemo/bioradiotherapy. <i>Radiotherapy and Oncology</i> , 2019, 130, 89-96.	0.6	23
71	Proton versus photon radiation-induced cell death in head and neck cancer cells. <i>Head and Neck</i> , 2019, 41, 46-55.	2.0	23
72	Reduced acute toxicity and improved efficacy from intensity-modulated proton therapy (IMPT) for the management of head and neck cancer. <i>Chinese Clinical Oncology</i> , 2016, 5, 54-54.	1.2	23

#	ARTICLE	IF	CITATIONS
73	Immune system and intestinal microbiota determine efficacy of androgen deprivation therapy against prostate cancer. , 2022, 10, e004191.		23
74	Prognostic significance of anti-p53 and anti-KRas circulating antibodies in esophageal cancer patients treated with chemoradiotherapy. BMC Cancer, 2012, 12, 119.	2.6	22
75	Quality of life after brachytherapy or bilateral nerve-sparing robot-assisted radical prostatectomy for prostate cancer: a prospective cohort. BJU International, 2018, 121, 540-548.	2.5	22
76	Low-Dose-Rate Definitive Brachytherapy for High-Grade Vaginal Intraepithelial Neoplasia. Oncologist, 2011, 16, 182-188.	3.7	21
77	Clinical outcomes after intensity-modulated proton therapy with concurrent chemotherapy for inoperable non-small cell lung cancer. Radiotherapy and Oncology, 2019, 136, 136-142.	0.6	21
78	Long-term Outcome of a Fissurectomy: A Prospective Single-Arm Study of 50 Operations out of 349 Initial Patients. Annals of Coloproctology, 2018, 34, 83-87.	2.0	20
79	Prophylactic cranial irradiation in lung cancer. Current Opinion in Oncology, 2010, 22, 94-101.	2.4	19
80	Functional Data Analysis in NTCP Modeling: A New Method to Explore the Radiation Dose-Volume Effects. International Journal of Radiation Oncology Biology Physics, 2014, 90, 654-663.	0.8	18
81	Prognostic impact of leukocyte counts before and during radiotherapy for oropharyngeal cancer. Clinical and Translational Radiation Oncology, 2017, 7, 28-35.	1.7	18
82	Pharmacological modulation of radiation-induced oral mucosal complications. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 2018, 22, 429-437.	1.4	18
83	Role of chemotherapy in 5000 patients with head and neck cancer treated by curative surgery: A subgroup analysis of the meta-analysis of chemotherapy in head and neck cancer. Oral Oncology, 2019, 95, 106-114.	1.5	18
84	Intensity-modulated proton therapy for oropharyngeal cancer reduces rates of late xerostomia. Radiotherapy and Oncology, 2021, 160, 32-39.	0.6	18
85	Meta-analysis of chemotherapy in nasopharynx carcinoma (MAC-NPC): An update on 26 trials and 7080 patients. Clinical and Translational Radiation Oncology, 2022, 32, 59-68.	1.7	18
86	Comprehensive Quantitative Evaluation of Variability in Magnetic Resonance-Guided Delineation of Oropharyngeal Gross Tumor Volumes and High-Risk Clinical Target Volumes: An R-IDEAL Stage 0 Prospective Study. International Journal of Radiation Oncology Biology Physics, 2022, 113, 426-436.	0.8	18
87	Busulfan-melphalan in high-risk neuroblastoma: the 30-year experience of a single institution. Bone Marrow Transplantation, 2016, 51, 1076-1081.	2.4	17
88	Systematic review and meta-analysis of phase I/II targeted therapy combined with radiotherapy in patients with glioblastoma multiforme: quality of report, toxicity, and survival. Journal of Neuro-Oncology, 2015, 123, 307-314.	2.9	16
89	Anemia and neutrophil-to-lymphocyte ratio are prognostic in p16-positive oropharyngeal carcinoma treated with concurrent chemoradiation. Papillomavirus Research (Amsterdam, Netherlands), 2018, 5, 32-37.	4.5	16
90	Prognostic value of tissue necrosis, hypoxia-related markers and correlation with HPV status in head and neck cancer patients treated with bio- or chemo-radiotherapy. Radiotherapy and Oncology, 2018, 126, 116-124.	0.6	16

#	ARTICLE	IF	CITATIONS
91	Looking Beyond the Numbers: Highlighting the Challenges of Population-Based Studies in Cancer Research. <i>Journal of Clinical Oncology</i> , 2016, 34, 2317-2318.	1.6	15
92	Pseudoprogression after high-dose busulfan-thiotepa with autologous stem cell transplantation and radiation therapy in children with brain tumors: Impact on survival. <i>Neuro-Oncology</i> , 2012, 14, 1413-1421.	1.2	14
93	Definitive radiotherapy for squamous cell carcinoma of the pyriform sinus. <i>Radiotherapy and Oncology</i> , 2012, 105, 232-237.	0.6	14
94	Sinonasal squamous cell carcinoma without clinical lymph node involvement. <i>Strahlentherapie Und Onkologie</i> , 2016, 192, 537-544.	2.0	14
95	Inflammatory bowel diseases activity in patients undergoing pelvic radiation therapy. <i>Journal of Gastrointestinal Oncology</i> , 2017, 8, 173-179.	1.4	14
96	Radiation-Induced Hypothyroidism After Radical Intensity Modulated Radiation Therapy for Oropharyngeal Carcinoma. <i>Advances in Radiation Oncology</i> , 2020, 5, 111-119.	1.2	14
97	Concurrent cisplatin and dose escalation with intensity-modulated radiotherapy (IMRT) versus conventional radiotherapy for locally advanced head and neck squamous cell carcinomas (HNSCC): GORTEC 2004-01 randomized phase III trial. <i>Radiotherapy and Oncology</i> , 2020, 150, 18-25.	0.6	14
98	Results and Survival of Locally Advanced AJCC 7th Edition T4a Laryngeal Squamous Cell Carcinoma Treated with Primary Total Laryngectomy and Postoperative Radiotherapy. <i>Annals of Surgical Oncology</i> , 2016, 23, 2596-2601.	1.5	13
99	Multicenter Randomized Double-Blind, Placebo-Controlled Trial GORTEC (Groupe Oncologie) Tj ETQq1 1 0.784314 rgBT /Overlock 10 of Head and Neck Cancer Patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, 590-595.	0.8	13
100	Long-term evaluation of urinary, sexual, and quality of life outcomes after brachytherapy for penile carcinoma. <i>Brachytherapy</i> , 2018, 17, 221-226.	0.5	13
101	Treatment strategies in early-stage oropharyngeal squamous cell carcinoma: a French national survey. <i>European Archives of Oto-Rhino-Laryngology</i> , 2016, 273, 2201-2207.	1.6	12
102	Patient-reported health-related quality of life for men treated with low-dose-rate prostate brachytherapy as monotherapy with 125-iodine, 103-palladium, or 131-caesium: Results of a prospective phase II study. <i>Brachytherapy</i> , 2018, 17, 265-276.	0.5	12
103	Horseshoe tract of anal fistula: bad luck or an avoidable extension? Lessons from 82 cases. <i>Colorectal Disease</i> , 2012, 14, 1512-1515.	1.4	11
104	Squamous cell carcinoma of the larynx with subglottic extension: is larynx preservation possible?. <i>Strahlentherapie Und Onkologie</i> , 2014, 190, 654-660.	2.0	11
105	Vocal fold mobility as the main prognostic factor of treatment outcomes and survival in stage II squamous cell carcinomas of the glottic larynx. <i>Journal of Laryngology and Otology</i> , 2015, 129, 903-909.	0.8	11
106	Clinical outcomes after interstitial brachytherapy for early-stage nasal squamous cell carcinoma. <i>Brachytherapy</i> , 2017, 16, 1021-1027.	0.5	11
107	Leukocytosis, prognosis biomarker in locally advanced head and neck cancer patients after chemoradiotherapy. <i>Clinical and Translational Radiation Oncology</i> , 2018, 12, 8-15.	1.7	11
108	Dramatic response to radiotherapy combined with vemurafenib. Is vemurafenib a radiosensitizer?. <i>European Journal of Dermatology</i> , 2014, 24, 265-267.	0.6	10

#	ARTICLE	IF	CITATIONS
109	Relationship between the time to locoregional recurrence and survival in laryngeal squamous-cell carcinoma. <i>European Archives of Oto-Rhino-Laryngology</i> , 2017, 274, 2267-2271.	1.6	10
110	Does East meet West? Towards a unified vision of the management of Nasopharyngeal carcinoma. <i>British Journal of Radiology</i> , 2019, 92, 20190068.	2.2	10
111	Individual patient data network meta-analysis using either restricted mean survival time difference or hazard ratios: is there a difference? A case study on locoregionally advanced nasopharyngeal carcinomas. <i>Systematic Reviews</i> , 2019, 8, 96.	5.3	10
112	Long-term outcomes and safety after reirradiation in locally recurrent nasopharyngeal carcinoma in a non-endemic area. <i>Strahlentherapie Und Onkologie</i> , 2021, 197, 188-197.	2.0	10
113	Laryngo-esophageal Dysfunction-free Survival in a Preservation Protocol for T3 Laryngeal Squamous-cell Carcinoma. <i>Anticancer Research</i> , 2016, 36, 6625-6630.	1.1	10
114	Patterns of disease events and causes of death in patients with HPV-positive versus HPV-negative oropharyngeal carcinoma. <i>Radiotherapy and Oncology</i> , 2022, 168, 40-45.	0.6	10
115	PARP Inhibition, a New Therapeutic Avenue in Patients with Prostate Cancer. <i>Drugs</i> , 2022, 82, 719-733.	10.9	10
116	On the Prevalence and Causes of Oncologist Burnout. <i>Journal of Clinical Oncology</i> , 2012, 30, 3029-3030.	1.6	9
117	Early PSA level decline is an independent predictor of biochemical and clinical control for salvage postprostatectomy radiotherapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 108.e15-108.e20.	1.6	9
118	¹⁸ F-fluorodeoxyglucose positron emission tomography to assess response after radiation therapy in anaplastic thyroid cancer. <i>Oral Oncology</i> , 2015, 51, 370-375.	1.5	9
119	Permanent prostate brachytherapy postimplant magnetic resonance imaging dosimetry using positive contrast magnetic resonance imaging markers. <i>Brachytherapy</i> , 2017, 16, 761-769.	0.5	9
120	Trends in Management of Oligometastatic Hormone-Sensitive Prostate Cancer. <i>Current Oncology Reports</i> , 2019, 21, 43.	4.0	9
121	NTCP Modeling of Late Effects for Head and Neck Cancer: A Systematic Review. <i>International Journal of Particle Therapy</i> , 2021, 8, 95-107.	1.8	9
122	TAXANE-CISPLATIN-5FU AS INDUCTION CHEMOTHERAPY IN LOCALLY ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA: AN INDIVIDUAL PATIENT DATA META-ANALYSIS OF THE MACH-NC GROUP. <i>Radiotherapy and Oncology</i> , 2011, 98, S6.	0.6	8
123	Toxicity of concomitant cetuximab and radiotherapy with or without initial taxane-based induction chemotherapy in locally advanced head and neck cancer. <i>Head and Neck</i> , 2016, 38, E905-10.	2.0	8
124	Helping patients make informed decisions. Two-year evaluation of the Gustave Roussy prostate cancer multidisciplinary clinic. <i>Clinical and Translational Radiation Oncology</i> , 2018, 12, 28-33.	1.7	8
125	Prognostic factors in patients with soft palate squamous cell carcinoma. <i>Head and Neck</i> , 2019, 41, 1441-1449.	2.0	8
126	Treatment of squamous cell carcinoma of the posterior pharyngeal wall: Radiotherapy versus surgery. <i>Head and Neck</i> , 2016, 38, E1722-9.	2.0	7

#	ARTICLE	IF	CITATIONS
127	Using Proton Beam Therapy in the Elderly Population: A Snapshot of Current Perception and Practice. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, 840-842.	0.8	7
128	Outcomes following laryngectomy refusal after insufficient response to induction chemotherapy. <i>Laryngoscope</i> , 2017, 127, 1791-1796.	2.0	7
129	Incidence of small lymph node metastases in patients with nasopharyngeal carcinoma: Clinical implications for prognosis and treatment. <i>Head and Neck</i> , 2017, 39, 305-310.	2.0	7
130	Outcomes in N3 Head and Neck Squamous Cell Carcinoma and Role of Upfront Neck Dissection. <i>Laryngoscope</i> , 2021, 131, E846-E850.	2.0	7
131	Re: Christopher J.D. Wallis, Refik Saskin, Richard Choo, et al. Surgery Versus Radiotherapy for Clinically-localized Prostate Cancer: A Systematic Review and Meta-analysis. <i>Eur Urol</i> 2016;70:21â€“30. <i>European Urology</i> , 2016, 70, e15-e16.	1.9	6
132	Radiation Therapy is Independently Associated with Worse Survival After R0-Resection for Stage II Non-small Cell Lung Cancer: An Analysis of the National Cancer Data Base. <i>Annals of Surgical Oncology</i> , 2017, 24, 1419-1427.	1.5	6
133	Predictive and Prognostic Value of CT Based Radiomics Signature in Head and Neck Squamous Cell Carcinoma Patients Treated With Concurrent Chemoradiation Therapy or Bioradiation Therapy and Its Added Value to Human Papillomavirus Status. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, S13.	0.8	6
134	Nedaplatin in nasopharyngeal cancer: the rebirth of platinum salts?. <i>Lancet Oncology</i> , The, 2018, 19, 429-431.	10.7	6
135	Induction chemotherapy followed by radiotherapy for N3 head and neck squamous cell carcinoma. <i>Head and Neck</i> , 2020, 42, 426-433.	2.0	6
136	Prognostic value and therapeutic implications of nodal involvement in head and neck mucosal melanoma. <i>Head and Neck</i> , 2021, 43, 2325-2331.	2.0	6
137	Radiotherapy for nasopharyngeal cancer. <i>Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique</i> , 2022, 26, 168-173.	1.4	6
138	Adjuvant or Salvage Radiation Therapy for Prostate Cancer after Prostatectomy: Current Status, Controversies and Perspectives. <i>Cancers</i> , 2022, 14, 1688.	3.7	6
139	OC-003: What is the best treatment in nasopharyngeal carcinoma? An individual patient data network meta-analysis. <i>Radiotherapy and Oncology</i> , 2015, 114, 6-7.	0.6	5
140	Comment on "Chemoradiotherapy regimens for locoregionally advanced nasopharyngeal carcinoma: A Bayesian network meta-analysis", published in <i>Eur J Cancer</i> 51 (2015), 1570â€“1579. <i>European Journal of Cancer</i> , 2016, 56, 183-185.	2.8	5
141	SP-010: Update of the meta-analysis of chemotherapy in head and neck cancer (MACH-NC). <i>Radiotherapy and Oncology</i> , 2017, 122, 9.	0.6	5
142	Radiation therapy to the primary in metastatic prostate cancer. <i>Current Opinion in Urology</i> , 2017, 27, 580-586.	1.8	5
143	Radiation-induced Neurocognitive Dysfunction in Head and Neck Cancer Patients. <i>Tumori</i> , 2017, 103, 319-324.	1.1	5
144	Meta-analysis of chemotherapy in nasopharyngeal carcinoma (MAC-NPC): An update on 4,798 patients.. <i>Journal of Clinical Oncology</i> , 2014, 32, 6022-6022.	1.6	5

#	ARTICLE	IF	CITATIONS
145	Efficacy and toxicity following salvage high-dose-rate brachytherapy for locally recurrent prostate cancer after radiotherapy. <i>Brachytherapy</i> , 2022, 21, 424-434.	0.5	5
146	In Regard to Yang et al. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 86, 811.	0.8	4
147	Feasibility of radiotherapy or chemoradiotherapy after taxane-based induction chemotherapy for nonoperated locally advanced head and neck squamous cell carcinomas. <i>Anti-Cancer Drugs</i> , 2014, 25, 1220-1226.	1.4	4
148	Clinical and Translational Radiation Oncology, a new player among the radiation oncology journals. <i>Clinical and Translational Radiation Oncology</i> , 2016, 1, 1.	1.7	4
149	Hypofractionation for prostate cancer: a word of caution. <i>Lancet Oncology</i> , The, 2016, 17, 406-407.	10.7	4
150	Salvage Radiation Therapy for Biochemical Recurrence After Radical Prostatectomy: Is Earlier Always Better?. <i>Journal of Clinical Oncology</i> , 2017, 35, 1489-1490.	1.6	4
151	Burnout among young European oncologists: a call for action. <i>Annals of Oncology</i> , 2017, 28, 1414-1415.	1.2	4
152	Readdressing the rationale of irradiation in stage I seminoma guidelines: a critical essay. <i>BJU International</i> , 2019, 124, 35-39.	2.5	4
153	Activity-Based Costing of Intensity-Modulated Proton versus Photon Therapy for Oropharyngeal Cancer. <i>International Journal of Particle Therapy</i> , 2021, 8, 374-382.	1.8	4
154	Penalized Poisson model for network meta-analysis of individual patient time-to-event data. <i>Statistics in Medicine</i> , 2021, 41, 340.	1.6	4
155	Radiotherapy for laryngeal cancers. <i>Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique</i> , 2022, 26, 206-212.	1.4	4
156	Absent benefit of accelerated concomitant chemoradiotherapy – Authors' reply. <i>Lancet Oncology</i> , The, 2012, 13, e136-e137.	10.7	3
157	Influence of the vocal cord mobility in salvage surgery after radiotherapy for early-stage squamous cell carcinoma of the glottic larynx. <i>European Archives of Oto-Rhino-Laryngology</i> , 2015, 272, 3013-3018.	1.6	3
158	MRI Simulation for LDR Prostate Brachytherapy: Can We Replace Ultrasound with MRI for Treatment Planning? Comparison of Pre-Planning, Day 0 and Day 30 MR Dosimetry. <i>Brachytherapy</i> , 2016, 15, S57.	0.5	3
159	What is the most effective treatment for head and neck squamous cell carcinoma? An individual patient data network meta-analysis from the MACH-NC and MARCH collaborative groups. <i>European Journal of Cancer</i> , 2017, 72, S101-S102.	2.8	3
160	Radiation Therapy is Independently Associated With Worse Survival After R0 Resection for Stage I-II Non-Small Cell Lung cancer: An Analysis of the National Cancer Data Base. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, 230.	0.8	3
161	ECOG-ACRIN 1308: Commentary on a Negative Phase II Trial. <i>Journal of Clinical Oncology</i> , 2017, 35, 1969-1970.	1.6	3
162	Are Individual patient data meta-analyses still needed today in oncology? A discussion focused on Head and Neck oncology. <i>Acta Oncologica</i> , 2019, 58, 1333-1336.	1.8	3

#	ARTICLE	IF	CITATIONS
163	Smoking and papillomavirus DNA in patients with p16-positive N3 oropharyngeal squamous cell carcinoma. <i>Head and Neck</i> , 2019, 41, 1039-1045.	2.0	3
164	The Reality of Randomized Controlled Trials for Assessing the Benefit of Proton Therapy: Critically Examining the Intent-to-Treat Principle in the Presence of Insurance Denial. <i>Advances in Radiation Oncology</i> , 2021, 6, 100635.	1.2	3
165	Relapses in metastatic germ-cell tumors and relationship to international guidelines compliance: A study from the Institut Gustave Roussy. <i>Journal of Clinical Oncology</i> , 2012, 30, 323-323.	1.6	3
166	A frequentist one-step model for a simple network meta-analysis of time-to-event data in presence of an effect modifier. <i>PLoS ONE</i> , 2021, 16, e0259121.	2.5	3
167	Best practice in brachytherapy. <i>Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique</i> , 2022, 26, 29-33.	1.4	3
168	Events prediction after treatment in HPV-driven oropharyngeal carcinoma using machine learning. <i>European Journal of Cancer</i> , 2022, 171, 106-113.	2.8	3
169	Choline Positron Emission Tomography/Computed Tomography for Selection of Patients for Salvage Strategies After Primary Local Treatment of Prostate Cancer and Rising Prostate-specific Antigen: Ready for Prime Time?. <i>European Urology</i> , 2017, 71, 349-350.	1.9	2
170	Lessons from the first 70 patients operated by doppler-guided haemorrhoidal artery ligation with mucopexy in a French team specialising in surgical proctology. <i>Journal of Coloproctology</i> , 2018, 38, 111-116.	0.1	2
171	Treating Metastatic Prostate Cancer With Local Therapies: Is It Still Wishful Thinking?. <i>Journal of Clinical Oncology</i> , 2018, 36, 2348-2349.	1.6	2
172	OC-010 Local recurrence of nasopharyngeal carcinomas outcomes after reirradiation. <i>Radiotherapy and Oncology</i> , 2019, 132, 9-10.	0.6	2
173	Pulsed Dose Rate Brachytherapy of Lip Carcinoma: Clinical Outcome and Quality of Life Analysis. <i>Cancers</i> , 2021, 13, 1387.	3.7	2
174	Contemporary Imaging Technologies for Men with Rising Prostate-specific Antigen After Radical Prostatectomy and Before Early Salvage Irradiation: Where Do We Stand?. <i>European Urology Oncology</i> , 2021, 4, 356-357.	5.4	2
175	Methodologies to Increase the Level of Evidence of Real-life Proton Therapy in Head and Neck Tumors. <i>International Journal of Particle Therapy</i> , 2021, 8, 328-338.	1.8	2
176	eLQ : A biologically-equivalent dose calculator available on iPhone, Android, and the web. <i>Practical Radiation Oncology</i> , 2011, 1, 212-213.	2.1	1
177	OC-0057: Meta-analysis of radiotherapy in head and neck cancers: exploratory analysis according to patient characteristics. <i>Radiotherapy and Oncology</i> , 2014, 111, S21.	0.6	1
178	2876 Radiomics feature quantification in patients with locally advanced head and neck carcinomas treated with chemoradiotherapy. <i>European Journal of Cancer</i> , 2015, 51, S582.	2.8	1
179	In Reply to Alber and Sahn. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 91, 679.	0.8	1
180	Permanent Seed Implantation Prostate Brachytherapy for Intermediate Risk Prostate Cancer: Efficacy and Toxicity Outcomes from a Prospective Cohort of 300 Patients. <i>Brachytherapy</i> , 2016, 15, S201.	0.5	1

#	ARTICLE	IF	CITATIONS
181	The Value of Brachytherapy for Intermediate-Risk Localized Prostate Cancer Using Icthm Outcomes and Time-Driven Activity-Based Costing: Results From a Phase 2 Prospective Trial of 300 Patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, E400-E401.	0.8	1
182	Prospective Cohort of Permanent Seed Implantation Prostate Brachytherapy for Intermediate Risk Prostate Cancer: Analysis of Patient Satisfaction and Interference with Daily Activities between 125-iodine, 103-palladium and 131-caesium. <i>Brachytherapy</i> , 2016, 15, S201-S202.	0.5	1
183	PD-028: Prognostic and predictive impact of HPV status in oropharyngeal cancer: the MARCH-HPV project. <i>Radiotherapy and Oncology</i> , 2017, 122, 17.	0.6	1
184	Prospective In Silico Study of the Feasibility and Dosimetric Advantages of MRI-Guided Dose Adaptation for Human Papillomavirus Positive Oropharyngeal Cancer Patients Compared With Standard IMRT. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, E699-E700.	0.8	1
185	EP-1245: A systematic review of dose-effect relationship in radiotherapy for head and neck plasmacytoma. <i>Radiotherapy and Oncology</i> , 2018, 127, S688-S689.	0.6	1
186	EP-1184 Target volume delineation for adaptive treatment in HNSCC is highly variable among experts. <i>Radiotherapy and Oncology</i> , 2019, 133, S655-S656.	0.6	1
187	Re: Marco Moschini, Emanuele Zaffuto, Pierre I. Karakiewicz, et al. External Beam Radiotherapy Increases the Risk of Bladder Cancer When Compared with Radical Prostatectomy in Patients Affected by Prostate Cancer: A Population-based Analysis. <i>Eur Urol</i> 2019;75:319-28. <i>European Urology</i> , 2019, 75, e96-e97.	1.9	1
188	Who dies from prostate cancer in a Western country? A multicenter analysis.. <i>Journal of Clinical Oncology</i> , 2013, 31, 211-211.	1.6	1
189	Second malignancy (SM) in prostate cancer patients treated with SBRT and other contemporary radiation techniques. <i>Radiotherapy and Oncology</i> , 2021, 164, 251-252.	0.6	1
190	A randomized phase III, factorial design, of cabazitaxel and pelvic radiotherapy in patients with localized prostate cancer and high-risk features of relapse.. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS5098-TPS5098.	1.6	1
191	Twitter as a Medical Media Among French Young Oncologists: Results from a National Survey. <i>Journal of Cancer Education</i> , 2023, 38, 319-324.	1.3	1
192	43 speaker UPDATE OF META-ANALYSES AND EBM LEVEL 1 ON: FRACTIONATION. <i>Radiotherapy and Oncology</i> , 2011, 99, S20.	0.6	0
193	7005 POSTER DISCUSSION PSA Measurement at the Fifth Week of Radiotherapy Is an Independent Predictor of Failure in Intermediate Risk Prostate Cancer Patients. <i>European Journal of Cancer</i> , 2011, 47, S485.	2.8	0
194	Early PSA Decline is an Independent Predictor of Recurrence for Salvage Post-Prostatectomy Radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 81, S426.	0.8	0
195	Intraprostatic Boost Using High-dose-rate Brachytherapy (HDR-BT) According to Gross Tumor Volume (GTV) Location for Prostate Cancer: A Dosimetric Feasibility Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 84, S399-S400.	0.8	0
196	Esthesioneuroblastomas: Bicentric Review of Clinical Features, Multimodal Treatment, and Long-term Outcome. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 84, S498-S499.	0.8	0
197	P107 Dosimetric evaluation of the feasibility of an intraprostatic boost according to gross-tumor-volumes (GTVs) location for prostate cancer patients treated with combined external beam radiotherapy (EBRT) and high-dose-rate brachytherapy (HDR-BT). <i>European Urology Supplements</i> , 2012, 11, 227.	0.1	0
198	Squamous Cell Carcinoma of the Larynx With Subglottic Extension: Is Larynx Preservation Possible?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 87, S451.	0.8	0

#	ARTICLE	IF	CITATIONS
199	Comparison of dose distribution between intensity modulated radiation therapy and dynamic arc therapy in and out-of-field for prostate cancer treatment plan. <i>Physica Medica</i> , 2013, 29, e39.	0.7	0
200	Vaginal Sparing Using a Mold in Anal Cancer Female Patients Treated With Intensity Modulated Radiation Therapy: A Dosimetric Feasibility Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 87, S335.	0.8	0
201	SP-0121: Brachytherapy as a Boost. Prostate. <i>Radiotherapy and Oncology</i> , 2013, 106, S45.	0.6	0
202	SP-0524: Activities 2012-2013 and report from the AGORA meeting. <i>Radiotherapy and Oncology</i> , 2013, 106, S202.	0.6	0
203	SP-0610: Will targeted agents improve the results of chemoradiation in high-risk HPV-negative head and neck cancers?. <i>Radiotherapy and Oncology</i> , 2014, 111, S238.	0.6	0
204	Reply to D. Tural et al. <i>Journal of Clinical Oncology</i> , 2014, 32, 259-260.	1.6	0
205	PD-0046: Outcome according to pelvic radiotherapy in the GETUG 12 phase III trial for high-risk localized prostate cancer. <i>Radiotherapy and Oncology</i> , 2015, 115, S22.	0.6	0
206	SP-0292: The issue of the quality of data in clinical trials. <i>Radiotherapy and Oncology</i> , 2015, 115, S148.	0.6	0
207	SP-054: Against the motion. <i>Radiotherapy and Oncology</i> , 2015, 114, 30.	0.6	0
208	A Dose-Escalation Study for High-Dose-Rate Brachytherapy Boost in Intermediate- and High-Risk Prostate Cancer Patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 93, E238-E239.	0.8	0
209	Are We Ready to Replace Postimplant CT Dosimetry? Permanent Prostate Brachytherapy Postimplant MRI Dosimetry Using Positive Contrast MRI Markers. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, E280-E281.	0.8	0
210	Relationship Between Radiation Therapy Dose and Overall Survival in Anaplastic Thyroid Cancer: Analysis of the National Cancer Data Base. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, E361.	0.8	0
211	How to Counsel Patients With Localized Prostate Cancer About Treatment Selection: Quality-of-Life Results of a Prospective Single-Institution Cohort. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, E534-E535.	0.8	0
212	Prospective Cohort of Permanent Seed Implantation Prostate Brachytherapy for Intermediate Risk Prostate Cancer: Patient Reported Outcomes and Comparison of Toxicity Profiles between 125-iodine, 131-cesium and 103-palladium. <i>Brachytherapy</i> , 2016, 15, S26.	0.5	0
213	Are We Ready to Replace Post-Implant CT Dosimetry? Permanent Prostate Brachytherapy Post-Implant MRI Dosimetry Using Positive Contrast MRI Markers. <i>Brachytherapy</i> , 2016, 15, S189-S190.	0.5	0
214	Toward a Model-Based Strategy for Patient Selection for Proton Therapy—External Validation of Normal Tissue Complication Probability Models on a Head and Neck Proton Cohort. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, S223.	0.8	0
215	EP-2009: Feasibility and early toxicity of HDR alone in pts with recurrent/locally advanced prostate cancer. <i>Radiotherapy and Oncology</i> , 2016, 119, S949-S950.	0.6	0
216	Intensity Modulated Proton (IMPT) Versus Photon (IMRT) Radiation Therapies: Comparing Patient-Reported Outcomes (PRO) in Patients With Oropharyngeal Cancer Undergoing Chemoradiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 94, 958.	0.8	0

#	ARTICLE	IF	CITATIONS
217	In Regard to Arthurs etÂal. International Journal of Radiation Oncology Biology Physics, 2017, 97, 440.	0.8	0
218	Early Quality of Life Outcomes and Patient Satisfaction Metrics for MRI-Assisted Prostate Brachytherapy Patients. International Journal of Radiation Oncology Biology Physics, 2017, 99, E230.	0.8	0
219	Two-Year Prospective Patient Reported Outcomes Related to Dysphagia After Intensity Modulated Proton Therapy for Oropharyngeal Cancer. International Journal of Radiation Oncology Biology Physics, 2017, 99, E341-E342.	0.8	0
220	Reported Outcomes and Toxicities for Inoperable, Stage II-III Nonâ€Small Cell Lung Cancer Patients Treated with Concurrent Chemotherapy and Intensity Modulated Proton Therapy. International Journal of Radiation Oncology Biology Physics, 2017, 99, E484-E485.	0.8	0
221	Clinical Relevance of Tumor Infiltrating Lymphocytes, PD-L1 Expression, and Correlation with HPV/P16 in Head and Neck Cancer Treated with Bio- or Chemoradiation Therapy. International Journal of Radiation Oncology Biology Physics, 2017, 99, S203-S204.	0.8	0
222	Outcomes Following Proton Therapy for the Treatment of Prostate Cancer: Efficacy and Toxicity Results from 2 Prospective Single Institution Cohorts. International Journal of Radiation Oncology Biology Physics, 2017, 99, E221.	0.8	0
223	SP-016: the value of proton therapy for head and neck malignancies: reducing side effects and improving outcomes. Radiotherapy and Oncology, 2017, 122, 12.	0.6	0
224	PO-0966: Prognostic value of tissue necrosis, CD34 MVD and CA-IX in head and neck cancer patients. Radiotherapy and Oncology, 2017, 123, S533-S534.	0.6	0
225	SP-0556: Clinical evidence for hypofractionation in prostate cancer what is the optimum?. Radiotherapy and Oncology, 2017, 123, S298.	0.6	0
226	OC-0400: Prognostic impact of tumor infiltrating lymphocytes and PD-L1 expression in head and neck cancers. Radiotherapy and Oncology, 2017, 123, S213.	0.6	0
227	EP-1324: Single-fraction HDR brachytherapy boost in combination to EBRT for prostate cancer. Radiotherapy and Oncology, 2017, 123, S710.	0.6	0
228	Prognostic Impact of Leukocyte Counts Before and During Radiation Therapy for Oropharyngeal Cancer. International Journal of Radiation Oncology Biology Physics, 2018, 100, 1336.	0.8	0
229	Two-Year Prospective Patient Reported Outcomes Related to Dysphagia After Intensity Modulated Proton Therapy for Oropharyngeal Cancer. International Journal of Radiation Oncology Biology Physics, 2018, 100, 1389.	0.8	0
230	In Regard to Sher et al. Practical Radiation Oncology, 2018, 8, 66-67.	2.1	0
231	Prognostic Impact of HPV-Associated p16 Expression and Smoking Status on Outcomes Following Radiation Therapy for Oropharyngeal Cancer: the MARCH-HPV Project. International Journal of Radiation Oncology Biology Physics, 2018, 100, 1332.	0.8	0
232	OC-0056: Evaluation of urinary, sexual and quality of life outcomes after brachytherapy for penile carcinoma. Radiotherapy and Oncology, 2018, 127, S24.	0.6	0
233	SP-0360: Our 3 new journals, update after 1 year: ctRO. Radiotherapy and Oncology, 2018, 127, S184.	0.6	0
234	OC-0489: TAM and HLA class I expression in relation to HPV and clinical outcome in head and neck cancer. Radiotherapy and Oncology, 2018, 127, S251-S252.	0.6	0

#	ARTICLE	IF	CITATIONS
235	SP-0579: Validation of photon-derived normal tissue complication probability models in a head and neck proton therapy cohort. Radiotherapy and Oncology, 2018, 127, S303.	0.6	0
236	SP-0652: Extreme hypofractionation for prostate cancer: is single fraction a future?. Radiotherapy and Oncology, 2018, 127, S346.	0.6	0
237	EP-1158: Prognostic factors and role of neck dissection in N3 head and neck cancers treated with radiotherapy. Radiotherapy and Oncology, 2018, 127, S649.	0.6	0
238	OC-0586 Immunological contexture basis of a prognostic radiomics signature in head and neck cancers. Radiotherapy and Oncology, 2019, 133, S307.	0.6	0
239	SP-0677 Oligometastatic Prostate SBRT: The How, What, Where and When. Radiotherapy and Oncology, 2019, 133, S355-S356.	0.6	0
240	Response to R. Jayaraj. Oral Oncology, 2020, 102, 104439.	1.5	0
241	Cancro dell'orofaringe. EMC - Otorinolaringoiatria, 2020, 19, 1-17.	0.0	0
242	Toxicities of tyrosine kinase inhibitors: Occurrence of hemoptysis and tracheo-oesophageal fistula in 150 patients with advanced thyroid cancer.. Journal of Clinical Oncology, 2014, 32, 6077-6077.	1.6	0
243	Radiographic-anatomy, natural history and extension pathways of parotid and submandibular gland cancers. Radiotherapy and Oncology, 2022, , .	0.6	0
244	The Post-Prostatectomy Setting: What to Do and When to Do. International Journal of Radiation Oncology Biology Physics, 2022, 113, 254.	0.8	0